hernexeos zongertinib tablets lung cancer 60mg

Description

Indication & Scope

Hernexeos® Zongertinib Tablets treats adult patients with unresectable or metastatic non-squamous non-small cell lung cancer harboring activating HER2 tyrosine kinase domain mutations detected by authorized diagnostic tests.

Mechanism: Zongertinib is an irreversible selective HER2 tyrosine kinase inhibitor. It covalently binds to cysteine residue C805 within the HER2 kinase domain, selectively blocks HER2-driven proliferative signaling with minimal off-target EGFR inhibition, suppressing HER2-mutant lung cancer cell proliferation and metastasis.
Drug class: Selective HER2 tyrosine kinase inhibitor; oral targeted anti-cancer small molecule.
Clinical use: First-line and post-platinum chemotherapy targeted treatment for HER2-mutant advanced NSCLC; demonstrates robust anti-tumor activity for patients previously treated with HER2 antibody-drug conjugates.

Specification

Generic Name	Zongertinib Tablets
Brand Name	Hernexeos
Ingredient	Zongertinib
Dosage Form	Tablets
Package	60mg*60 tablets/box
Conditions Treated	Locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 tyrosine kinase domain activating mutations
Taboos	Severe hypersensitivity to zongertinib or tablet inactive ingredients; patients with untreated severe interstitial lung disease
Place of origin	Quinta Sao Pedro, Sete Casas, Loures, 2674-506, Portugal
Prescription type	Prescription-only
Storage Conditions	Store in original closed bottle at 20°C to 25°C, avoid high humidity and direct light exposure
Manufacturer	Boehringer Ingelheim International GmbH
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	HJ20250104
Approval Date	May 19, 2026
Shelf Life	36 months

How to use ?

Recommended Dose: 60 mg taken orally once daily for adult patients.

Time: Consistent daily dosing at the same hour, can be administered with or without food.

Instructions for use: Swallow tablets intact with plain water; do not split or crush. Monitor pulmonary function and liver enzymes monthly throughout treatment.

Interaction: Strong CYP3A4 inhibitors significantly elevate zongertinib plasma concentration, requiring dose reduction; proton pump inhibitors do not alter overall drug absorption efficacy.

Side effects:

1. Common reactions: diarrhea, fatigue, stomatitis, paronychia, dry skin, elevated transaminases.

2. Severe rare adverse events: interstitial lung disease, grade 3 diarrhea, severe cutaneous toxicity.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support